GDF15 and neurodegenerative disease: Therefore, reduced levels of GDF15 and γ-GT imply the attenuation of existing mitochondrial and oxidative stresses by HBOT, which suggest therapeutic potential for metabolic diseases or neurodegenerative diseases associated with oxidative stress and mitochondrial dysfunction.